Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Puma Biotechnology, Inc.NASDAQ: PBYI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$3.75M, compared with $2.97M a year earlier. Trailing-twelve-month net income was $24.38M. Over 3 fiscal years it compounded at +2396.3% a year.

Context

  • Net income amounted to 13.6% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $19.25M (-38.1%) for the fiscal year ending Dec 2026, a slowdown from the +2.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.75M-127.9% QoQ
Last fiscal yearDec 2025
$31.11M+2.8% YoY
LTMMar 2026
$24.38M-35.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-226.2%-63.7%+162.5 pp
1 year+2.8%-38.1%-40.9 pp
3-year CAGR+2396.3%-37.5%-2433.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
31.11M USD
Year-over-year change
+2.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.9% is the 9th highest of 11, against a peer median of +13.4%.
  • Net income amounts to 10.7% of revenue for PBYI, versus a peer median of 228.6%.
PBYI Competitors
Net Income for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$208M USD+106.9%-2.1%—
VSTMVerastem, Inc.LTM Mar 2026$193.96M USD+30.3%+41.6%391.2%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥150.96M CNY-47.8%-67.2%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M USD+14.0%+65.2%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$135.21M USD+1.8%+13.3%—
NUVBNuvation Bio Inc.LTM Jun 2026$112.24M USD+155.3%+25.2%66.1%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$43.21M USD-948.8%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$35.52M CAD+12.8%+16.7%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M USD-35.9%+2396.3%10.7%
Peer median (excluding PBYI) —+13.4%+13.3%228.6%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.